文献速递类风湿关节炎

类风湿关节炎患者肺炎预后:入院前用药与疾病活动性的作用

Prognosis of pneumonia in patients with rheumatoid arthritis: the role of medication and disease activity prior to admission a population-based cohort study.
PubMed 文献 · RMD Open · 2020-01-01

基于人群队列研究比较类风湿关节炎(RA)与非RA肺炎住院患者的90天死亡率,发现RA并未整体增加肺炎死亡风险(调整HR 1.05)。但入院前30-180天CRP≥20 mg/L的RA患者死亡风险显著升高(调整HR 4.98)。

要点

  • RA患者肺炎住院90天死亡率19.9%,与非RA患者18.9%相近,调整HR 1.05。
  • 入院前CRP≥20 mg/L的RA患者肺炎死亡风险显著增加,调整HR 4.98。
  • 泼尼松使用和无RA治疗相比甲氨蝶呤单药有升高死亡趋势,但置信区间包含1。

核心结论

  • 整体上RA不增加肺炎住院后的死亡率,但入院前高RA疾病活动性预测肺炎死亡率增加,且不受泼尼松使用影响。

研究设计与样本

  • 基于人群的队列研究,纳入52 577例首次因肺炎住院的患者,其中1220例(2.3%)患有RA,比较90天死亡率和调整HR。

主要发现

  • RA患者90天死亡率为19.9%,非RA患者为18.9%,调整90天HR为1.05(95%CI 0.92-1.19)。
  • 相比CRP<8 mg/L,CRP≥20 mg/L的RA患者调整90天HR为4.98(95%CI 2.19-11.36)。
  • 相比甲氨蝶呤单药,泼尼松(HR 1.43,95%CI 0.91-2.22)和无RA治疗(HR 1.35,95%CI 0.85-2.14)有增加90天死亡率的趋势。
  • 相比使用泼尼松且CRP低的患者,高CRP在使用泼尼松者中HR为3.09(95%CI 1.25-7.65),未使用者中HR为2.35(95%CI 0.94-5.87)。

临床怎么用

  • 对RA患者应关注入院前疾病活动性(如CRP水平),高CRP提示肺炎预后不良风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with rheumatoid arthritis (RA) experience an increased risk of infections, but the prognosis of infections is unclear. We examined if patients with RA have worse outcomes from pneumonia than non-RA individuals. METHODS: In a population-based cohort study, we computed 90-day mortality rates and crude and adjusted HRs comparing pneumonia patients with and without RA. Among patients with RA, we evaluated prognostic effects of RA medications including prednisolone and disease activity as assessed by C reactive protein (CRP) or platelet levels measured 30-180 days before admission to avoid any influence from the subsequent infection. RESULTS: Among 52 577 patients hospitalised for the first time with pneumonia, 1220 (2.3%) had RA. The 90-day mortality was 19.9% for patients with RA and 18.9% for non-RA patients (adjusted 90-day HR of 1.05 (95% CI 0.92 to 1.19)). Compared with CRP levels <8 mg/L, CRP levels ≥20 mg/L predicted increased mortality in patients with RA with adjusted 90-day HRs of 4.98 (95% CI 2.19 to 11.36). Compared with methotrexate monotherapy, both prednisolone (HR 1.43 (95% CI 0.91 to 2.22)) and no RA therapy (HR 1.35 (95% CI 0.85 to 2.14)) tended to increase 90-day mortality. Compared with patients who used prednisolone and had low CRP levels, high CRP predicted increased mortality both in patients who used prednisolone (HR 3.09, 95% CI 1.25 to 7.65) and those who did not (HR 2.35, 95% CI 0.94 to 5.87). CONCLUSIONS: Overall, RA does not increase mortality following hospitalisation for pneumonia. However, high RA disease activity prior to admission predicts increased pneumonia mortality in patients regardless of prednisolone use.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Holland-Fischer M, Thomsen RW, Tarp U, et al. Prognosis of pneumonia in patients with rheumatoid arthritis: the role of medication and disease activity prior to admission a population-based cohort study. RMD Open. 2020. PMID: 32396523. doi:10.1136/rmdopen-2019-001102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。